AUS
NZ
UK
CA
USA
IND
Microba Life Sciences Limited (ASX:MAP) has successfully closed a capital raising round through an institutional Placement and Share Purchase Plan (SPP), collectively generating approximately $5.41 million before expenses. The capital will drive the expansion of Microba's core microbiome diagnostics services across Australia and the United Kingdom, support the launch of a new testing product, and provide working capital. All resolutions required for issuing securities under the SPP and the second tranche of the Placement were approved at the company’s general meeting on 24 July 2026.
Key Points
- Microba Life Sciences Limited (ASX:MAP) completed a capital raise totaling about $5.41 million before costs via an institutional Placement and Share Purchase Plan.
- The SPP issued 8,150,000 New Shares at $0.05 each, raising $407,500, with all valid applications fully allocated and no scale-back applied.
- Eligible SPP shareholders will receive one free attaching New Option per New Share issued, exercisable at $0.0625 and expiring three years from issuance.
- New Shares and New Options are scheduled for issuance on 29 July 2026, with trading of SPP shares commencing on 30 July 2026.
- Raised funds will support Microba’s ongoing clinical adoption growth of microbiome testing in Australia and the UK, along with the rollout of a new testing product.
Microba’s Microbiome Diagnostics Operations and Market Strategy
Microba Life Sciences Limited operates at the forefront of microbiome health, offering clinical-grade microbiome testing solutions aimed at improving health outcomes. The company’s primary focus is on microbiome diagnostics within Australia and the United Kingdom, leveraging proprietary collaboration tools to facilitate clinical adoption of its tests. Microba positions itself as a leader in microbiome science and insights, supporting healthcare providers and patients with advanced diagnostic capabilities.
According to the announcement, Microba’s mission is to provide clinical-grade microbiome tests that enable better health decisions by patients and healthcare professionals. Its revenue model is based on delivering diagnostic services to healthcare practitioners and patients in its key markets. The capital raised will fuel strategic growth by expanding its diagnostics business across Australia and the UK.
Structure of the $5.41 Million Capital Raise
The capital raise consisted of two components: an institutional Placement announced on 12 June 2026 and a Share Purchase Plan (SPP) that closed on 22 July 2026. Together, these raised approximately $5.41 million before costs, with $5.0 million from the Placement and $407,500 from the SPP. This dual approach enabled participation from both institutional investors and eligible retail shareholders at the same share price, with no brokerage or fees for SPP participants.
The Placement was completed in two tranches: the first tranche of 91,344,455 New Shares settled on 17 June 2026, and the second tranche of 8,659,785 New Shares required shareholder approval, which was granted at the 24 July 2026 general meeting. This staged process allowed immediate funding while managing regulatory and shareholder approvals separately, reflecting a comprehensive capital raising strategy engaging both institutional and retail investors.
Share Purchase Plan Details and Shareholder Participation
The SPP was offered to eligible shareholders in Australia and New Zealand on identical terms to institutional investors, under a prospectus dated 19 June 2026 issued pursuant to section 713 of the Corporations Act 2001 (Cth). Eligible shareholders subscribed for New Shares at $0.05 each, with all valid applications fully satisfied and no scale-back applied.
The SPP raised $407,500 through issuing 8,150,000 New Shares at $0.05 each. Additionally, eligible SPP participants will receive 8,150,000 free attaching New Options exercisable at $0.0625 and expiring three years from issue. The New Shares rank equally with existing ordinary shares, ensuring equal rights and entitlements for new shareholders. The free attaching options serve as an incentive to encourage retail shareholder engagement.
Shareholder and Regulatory Approvals for Placement Second Tranche
Issuance of securities under the SPP and the second Placement tranche required shareholder approval, which was obtained at the general meeting on 24 July 2026. Following approval, Microba issued 8,659,785 New Shares for the second tranche alongside SPP securities and free attaching options.
The approval underscores strong investor support for Microba’s capital expansion and strategic plans. The swift transition from approval on 24 July 2026 to securities issuance on 29 July 2026 demonstrates an efficient process, compliant with ASX Listing Rules and the Corporations Act 2001 (Cth), ensuring equal disclosure and investment opportunities for institutional and retail investors.
New Options Terms and Investment Incentives
As part of the capital raise, Microba issued free attaching New Options to both Placement and SPP investors on a one-for-one basis with shares issued. Institutional investors received 100,004,240 New Options in total, while SPP investors received 8,150,000 New Options. All options are exercisable at $0.0625 and expire three years post-issuance, providing a three-year exercise window.
These options offer investors potential upside if Microba’s share price exceeds the $0.0625 exercise price within three years. For Microba, they represent a future capital source if exercised. The exercise price is a 25% premium over the $0.05 share issue price, setting a performance benchmark for option holders.
Allocation of Capital and Growth Strategy
Microba will use the raised funds to strengthen its balance sheet and accelerate clinical adoption of microbiome testing in Australia and the UK. The capital will also support launching a new testing product currently in development and cover working capital needs to maintain operational liquidity.
This funding strategy highlights Microba’s focus on geographic expansion and product innovation within the microbiome diagnostics market. Emphasizing clinical adoption in established healthcare markets and introducing new testing products positions Microba to grow revenue streams from healthcare providers and patients. Allocating capital to working capital ensures operational flexibility during growth.
Timeline for Issuance and Trading of New Securities
Microba plans to issue New Shares and New Options from both the SPP and Placement on 29 July 2026. Trading of SPP shares is expected to begin on 30 July 2026, with holding statements dispatched on 31 July 2026. These dates are indicative and may be adjusted at the company’s discretion, subject to ASX and regulatory requirements.
The rapid settlement timeline facilitates prompt market availability of new securities following shareholder approval. The one-day gap between issuance and trading allows for administrative processing, while the holding statements provide formal confirmation to investors within days.
Capital Raising Context and Institutional Investor Backing
The initial institutional Placement announced on 12 June 2026 raised $5.0 million before costs, with first tranche settlement on 17 June 2026 at $0.05 per share. The subsequent SPP offered retail shareholders the same price opportunity, reinforcing Microba’s commitment to equitable shareholder treatment.
CEO Luke Reid expressed appreciation for shareholder support and highlighted that the capital raise strengthens Microba’s position to expand clinical adoption of its microbiome testing. Reid emphasized confidence in market opportunities and the intent to leverage funds to grow existing markets and launch new products. The capital raise marks a key milestone for Microba’s growth ambitions.
Industry Landscape and Competitive Position in Microbiome Diagnostics
Microba operates in the expanding microbiome diagnostics and personalized medicine sector, which has seen significant investment and research. The human microbiome is a critical focus area with applications in gastroenterology, metabolic health, immunology, and mental health. Commercial microbiome testing is a growing field where early clinical credibility and adoption are key competitive advantages.
Microba’s clinical-grade microbiome testing services in Australia and the UK target developed healthcare markets with advanced diagnostic capabilities. The company’s focus on clinical adoption and new product development positions it to expand diagnostic offerings and address a broader range of clinical conditions. The capital raised will enable Microba to compete effectively and scale as microbiome testing gains wider clinical acceptance.
Investor Risks and Operational Challenges
Investors should be aware of risks related to Microba’s business and market environment. The microbiome diagnostics sector is still emerging, with ongoing clinical research and regulatory scrutiny. Success depends on acceptance by healthcare providers and patients in Australia and the UK. Reimbursement policies from government or private insurers can significantly impact demand.
Expansion into new products and markets involves execution risks including validation, regulatory approvals, and market adoption timelines. Competitive pressures from larger diagnostics firms and other microbiome testing providers may limit market share and pricing power. These factors introduce uncertainties affecting Microba’s ability to realize anticipated benefits from the capital raise.
